Carlsmed’s (CARL) “Buy” Rating Reiterated at BTIG Research

Posted by Francis Steltz on Oct 1st, 2026

BTIG Research reiterated their buy rating on shares of Carlsmed (NASDAQ:CARL – Free Report) in a report released on Monday,Benzinga reports. BTIG Research currently has a $23.00 price objective on the stock.

A number of other analysts have also weighed in on the stock. Truist Financial raised their target price on shares of Carlsmed from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Needham & Company LLC initiated coverage on Carlsmed in a research note on Wednesday, July 1st. They issued a “buy” rating and a $17.00 price target for the company. Weiss Ratings upgraded Carlsmed from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Wall Street Zen raised Carlsmed from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $19.25.

Check Out Our Latest Report on Carlsmed

Carlsmed Stock Down 0.1%

Shares of NASDAQ CARL opened at $14.07 on Monday. The company has a market cap of $384.11 million, a price-to-earnings ratio of -9.84 and a beta of 1.95. The company has a current ratio of 8.84, a quick ratio of 8.66 and a debt-to-equity ratio of 0.18. Carlsmed has a 12 month low of $8.50 and a 12 month high of $17.23. The stock has a 50-day moving average price of $14.58 and a two-hundred day moving average price of $12.08.

Carlsmed (NASDAQ:CARL – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. The company had revenue of $18.94 million for the quarter. Carlsmed had a negative net margin of 57.42% and a negative return on equity of 38.06%. As a group, analysts forecast that Carlsmed will post -1.5 earnings per share for the current fiscal year.

Institutional Trading of Carlsmed

Institutional investors have recently modified their holdings of the business. Jupiter Topco LLC acquired a new position in Carlsmed during the 2nd quarter worth about $12,992,000. Parkman Healthcare Partners LLC acquired a new stake in shares of Carlsmed in the second quarter valued at about $6,200,000. BlackRock Inc. acquired a new stake in shares of Carlsmed in the second quarter valued at about $5,528,000. KCM Capital Inc bought a new position in shares of Carlsmed during the first quarter worth about $1,810,000. Finally, Janus Henderson Group PLC lifted its stake in shares of Carlsmed by 7.6% in the first quarter. Janus Henderson Group PLC now owns 1,227,452 shares of the company’s stock worth $11,108,000 after acquiring an additional 86,834 shares during the period.

About Carlsmed

(Get Free Report)

Carlsmed, Inc is a medical technology company focused on improving outcomes for patients undergoing complex spinal surgery. The company develops personalized implants and surgical solutions designed to help spine surgeons address the anatomical needs of individual patients, particularly those with adult spinal deformity and other challenging spinal conditions.

Its principal product platform, aprevo, uses patient-specific planning and implant design to support spinal reconstruction procedures.